IBV genotype QX causes suficient disease in Europe for several commercial companies to have started developing live attenuated vaccines. Here, one of those vaccines (L1148) was fully consensus sequenced alongside its progenitor ield strain (1148-A) to determine vaccines markers, thereby enabling detection on farms. Twenty eight single nucleotide substitutions were associated with the 1148-A attenuation, of which any combination can identify vaccine L1148 in the ield. Sixteen substitutions resulted in amino acid coding changes of which half were in spike. One change in the 1b gene altered the normally highly conserved inal 5 nucleotides of the transcription regulatory sequence of the S gene, common to all IBV QX genes. No mutations can currently be associated with the attenuation process. Field vaccination strategies would greatly beneit by such comparative sequence data being mandatorily submitted to regulators prior to vaccine release following a successful registration process
Listorti V., L.A. (2017). IDENTIFICAZIONE DI MARKER MOLECOLARI PER LA DIFFERENZIAZIONE DI UN VACCINO IBV GENOTIPO QX. Parma : La Ducale Srl.
IDENTIFICAZIONE DI MARKER MOLECOLARI PER LA DIFFERENZIAZIONE DI UN VACCINO IBV GENOTIPO QX
Listorti V.Writing – Original Draft Preparation
;Catelli E.Writing – Review & Editing
;Lupini C.Membro del Collaboration Group
;
2017
Abstract
IBV genotype QX causes suficient disease in Europe for several commercial companies to have started developing live attenuated vaccines. Here, one of those vaccines (L1148) was fully consensus sequenced alongside its progenitor ield strain (1148-A) to determine vaccines markers, thereby enabling detection on farms. Twenty eight single nucleotide substitutions were associated with the 1148-A attenuation, of which any combination can identify vaccine L1148 in the ield. Sixteen substitutions resulted in amino acid coding changes of which half were in spike. One change in the 1b gene altered the normally highly conserved inal 5 nucleotides of the transcription regulatory sequence of the S gene, common to all IBV QX genes. No mutations can currently be associated with the attenuation process. Field vaccination strategies would greatly beneit by such comparative sequence data being mandatorily submitted to regulators prior to vaccine release following a successful registration processI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
